OR WAIT 15 SECS
Acorda’s Chelsea, MA facility will serve as a global center of excellence in the Catalent network for spray-dried dispersion and dry powder encapsulation and packaging.
Catalent announced on Jan. 13, 2021 that it will acquire the manufacturing and packaging operations of Acorda Therapeutics, a US-based biotechnology company.
Through the agreement, Catalent will have access to Acorda’s 90,000-ft2 Chelsea, MA facility, which will serve as a global center of excellence in the Catalent network for spray-dried dispersion and dry powder encapsulation and packaging, Catalent said in a company press release. Additionally, Catalent will handle the commercial manufacture of Acorda’s INBRIJA, a prescription medicine used to treat hypomobility or off episodes in adults with Parkinson’s disease treated with regular carbidopa/levodopa medicine.
"Catalent is a premier partner to companies working on multiple forms of inhaled drug delivery, from early-stage development to commercial-scale supply," said Jonathan Arnold, president of Oral and Specialty Delivery at Catalent, in the press release. “This acquisition complements our existing US-based capabilities in metered-dose and nasal inhalation by adding an experienced team of people and a premier facility enabling us to provide customers with extended capabilities for commercial-scale filling and packaging of dry powder inhalers.”